NEW YORK, NY / ACCESSWIRE / August 8, 2023 / Levi & Korsinsky, LLP notifies investors in BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (NASDAQ:BTAI) of a class action securities lawsuit.
The lawsuit on behalf of BioXcel investors has been commenced in the United States District Court for the District of Connecticut. Affected investors purchased or otherwise acquired certain BioXcel Therapeutics, Inc. securities between December 15, 2021 and June 28, 2023. Follow the link below to get more information and be contacted by a member of our team:
https://zlk.com/pslra-1/bioxcel-lawsuit-submission-form?prid=43207&wire=1
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500. There is no cost or obligation to you.
BioXcel Therapeutics, Inc. NEWS - BTAI NEWS
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) the Company lacked adequate internal controls over protocol adherence and data integrity; (2) as a result, the Company's principal investigator failed to adhere to the informed consent form approved by the Institutional Review Board; (3) the Company's principal investigator failed to maintain adequate case histories for certain patients whose records were reviewed by the FDA; (4) the Company's principal investigator fabricated email correspondence with a pharmacovigilance safety vendor that was then provided to the FDA; (5) the foregoing would negatively impact the Company's ability to obtain regulatory approval of BXCL501 for the treatment of agitation associated with dementia in patients with probable Alzheimer's disease; and (6) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
WHAT THIS MEANS TO SHAREHOLDERS: If you suffered a loss in BioXcel during the relevant timeframe, you have until September 5, 2023 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. Discuss your rights with our legal team without cost or obligation.
PROTECT YOUR FINANCIAL INTERESTS: Complete this brief submission form https://zlk.com/pslra-1/bioxcel-lawsuit-submission-form?prid=43207&wire=1 or call 212-363-7500 to discuss the case.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
55 Broadway, 4th Floor Suite #427
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP